Keyword: Teva Pharmaceutical
After a year as the second-highest-paid biopharma exec , Teva CEO Kåre Schultz got a big pay cut in 2019—with an extension to ease the sting.
Chloroquine and hydroxychloroquine aren't approved for COVID-19, but they're getting a lot of attention. Companies will supply a mass of tablets.
Teva's Ajovy rollout just scored a big win in England, thanks to a recommendation from cost watchdogs there.
The state of New York will delay a key opioid bellwether trial in a move that could free drugmakers to aggressively pursue global settlements.
Teva's latest smart inhaler, recently approved by the FDA, rounds out its portfolio of Digihaler products that connect to apps for data and tracking.
Bristol-Myers Squibb is moving to end a seven-year Medicaid rebate lawsuit with an "agreement in principle" it offered the plaintiff in January.
It took four tries over four years, but Perrigo has finally gotten FDA approval of its generic of Teva’s tricky-to-make ProAir HFA asthma inhaler.
In an interview with Israel's Calcalist, Teva CEO Kåre Schultz shared details of his approach to the company's turnaround.
With CGRPs on the rise, Allergan's Botox is holding onto neurologist support in migraine patients. That preference could be a big win for AbbVie.